What is the enterprise value (EV) for Lyell Immunopharma, Inc. (LYEL)?

NAME	MARKET CAP	ENTERPRISE VALUE (EV)
Lyell Immunopharma, Inc. (LYEL)	$213.71M	$153.53M
Anbio Biotechnology Class A Ordinary Shares (NNNN)vs ›	$214.19M	$206.42M
Prelude Therapeutics Incorporated (PRLD)vs ›	$214.64M	$205.96M
Niagen Bioscience Inc (NAGE)vs ›	$214.64M	$150.23M
Compugen Ltd. (CGEN)vs ›	$211.71M	$204.46M
Entrada Therapeutics, Inc. (TRDA)vs ›	$209.77M	$159.04M
Electra Therapeutics Inc. (ETRA)vs ›	$208.94M	N/A
Pro-Dex, Inc. (PDEX)vs ›	$207.99M	$217.89M
Whitehawk Therapeutics Inc (WHWK)vs ›	$206.66M	$121.43M
Sionna Therapeutics, Inc. (SION)vs ›	$205.89M	$150.63M

Enterprise Value Calculation

Market Cap

$213.71M

Total Debt

$0.00

−

Cash

$60.18M

Enterprise Value

$153.53M

EV-Based Valuation Multiples

EV/EBITDA

N/A

EV/Sales

6580.1x

EV/FCF

N/A

Why use EV instead of Market Cap?

EV accounts for debt - an acquirer must pay or assume it
EV deducts cash - the acquirer effectively receives it
EV enables fair comparison of companies with different capital structures
EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral

Enterprise Value (EV) Formula & Definition

Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Enterprise Value (EV) FAQ

What is the enterprise value (EV) for Lyell Immunopharma, Inc. (LYEL)?: The enterprise value (EV) for LYEL stock is $153.53M.

About Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

South San Francisco, CA

161 employees

www.lyell.com

Healthcare / Biotechnology